drugset / Trial / NCT01448824
A Study of LY2484595 on Pharmacokinetics in Healthy Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
This is a 2-part study. Part 1 is to determine the safety and tolerability in healthy participants of increasing daily doses of LY2484595 for 14 days to achieve a blood level of LY2484595 much higher than what is needed for therapy. The amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it will be determined. The effect of the study drug on factors in the blood related to cholesterol will be measured. Part 2 is to determine how ketoconazole affects how much of the study drug, LY2484595, gets into the bloodstream and how long it takes to get rid of it. Information about any side effects that may occur will also be collected.
Timeline
- Start
- 2011-10
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evacetrapib | Small molecule | 100 mg | Oral |
| Subject | Evacetrapib | Small molecule | 300 mg | Oral |
| Subject | Evacetrapib | Small molecule | 600 mg | Oral |
| Subject | Evacetrapib | Small molecule | 1200 mg | Oral |
| Subject | Evacetrapib | Small molecule | 1800 mg | Oral |
| Subject | Ketoconazole | Small molecule | 400 mg | Oral |
Indications
No indication recorded.